test directorySearch Results
Click here to search again.
Test Name:
Hepatitis C Virus Antibody, Supplemental Immunoblot Assay (RIBA)
- SBMF No:
28181 - Performance Lab Name:
Blood Bank Services - Test Mnemonic:
HCV SIA - ABN:
May be required – Medical Necessity - CPT Code:
86804 - LOINC Code:
44813-4; 23871-7; 11077-5; 48767-8; 23870-9; 9610-7 - Also Known As:
HCV RIBA
HCV SIA
SIA (Supplemental Immunoblot Assay)
RIBA (Recombinant Immunoblot Assay)
Recombinant Immunoblot Assay - Spec Type:
Serum - Spec Container:
Gold top (SST) or red top (serum) tube - Alt Spec Type:
Plasma - Alt Spec Container:
Lavender top (EDTA) tube or green top (lithium heparin) tube - Pref Vol:
1.0 mL - Min Vol:
0.5 mL - Fasting:
No - Spec Collect:
Routine venipuncture - Spec Process:
Serum sample tubes, clot 30 minutes
Promptly centrifuge 15 minutes
Immediately transfer serum or plasma to separate plastic tube
Properly centrifuged gel barrier tube sample does not require transfer of serum to separate tube - Spec Store Transport:
Refrigerated - Spec Stability:
1 week refrigerated (2-8°C)
Greater than 1 week, freeze (-20°C) – Do not use frost-free units that undergo repeated freeze/thaw cycles - Methodology:
Recombinant Immunoblot Assay (ACHIRON® RIBA™ HCV 3.0 SI) - Use:
This supplemental hepatitis C virus antibody test is a more specific, confirmatory test run on serum or plasma samples found to be repeatedly reactive by an HCV antibody screening test (e.g., HCV Antibody by EIA) - Clinical Significance:
Several assays are available to aid in the diagnosis of hepatitis C virus infection. The common tests include the enzyme immunoassays (EIAs), which detect antibodies to the core and nonstructural genes; the recombinant immunoblot assays (RIBAs), which detect those antibodies using an immunoblot format; and polymerase chain reaction (PCR)-based assays for the qualitative and quantitative determination of HCV RNA. Additional tests available for the evaluation of liver disease include ALT levels and liver biopsy. Patients without apparent liver disease or those who are low risk: In individuals with no risk factors for HCV infection, a negative anti-HCV by EIA can be used to rule out HCV infection. A patient with a positive EIA result should be further tested for HCV RNA by PCR, using either the qualitative or quantitative assay. If the PCR is positive, the patient has HCV infection. If the PCR is negative, the patient should be further tested using an anti-HCV by RIBA. A negative RIBA indicates that the EIA is likely a false positive. A positive RIBA following a negative PCR indicates that the patient had HCV infection but does not currently have viremia. These patients may have completely recovered from the infection, or the infection may be in a dormant state. While indeterminate RIBA results are possible, they occur less frequently with the third generation RIBA. - Reference Range:
Hepatitis C Immunoblot Assay: Non-reactive - Day Run:
Thu - Time Run:
8:00 am - Time Reported:
5:00 pm - Test Type:
INFECTIOUS ANTIBODY
